A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
Open Access
- 26 June 2023
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (8) , 1169-1182
Abstract
Background and Objective Relugolix is a gonadotropin-releasing hormone receptor antagonist. Relugolix 40-mg monotherapy is associated with vasomotor symptoms and long-term bone mineral density loss due to hypoestrogenism. This study assessed whether the addition of estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg to relugolix 40 mg (relugolix combination therapy) provides systemic E2 concentrations in the 20–50 pg/mL range to minimize these undesirable effects. Methods This was a randomized, open-label, parallel-group study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of relugolix 40 mg alone or in combination with E2 1 mg and NETA 0.5 mg in healthy premenopausal women. Eligible women were randomized 1:1 to receive relugolix alone or relugolix plus E2/NETA for 6 weeks. Study assessments included pharmacokinetic parameters of E2, estrone, and relugolix in both treatment groups, and norethindrone in the relugolix plus E2/NETA treatment group at weeks 3 and 6. Results Median E2 24 h average concentrations with the relugolix plus E2/NETA group (N = 23) were 31.5 pg/mL, 26 pg/mL higher compared with the relugolix-alone group (6.2 pg/mL) (N = 25). There were 86.4% of participants in the relugolix plus E2/NETA group who had E2 average concentrations exceeding 20 pg/mL, the threshold expected to minimize bone mineral density loss, compared with 21.1% in the relugolix-alone group. Both treatments were generally safe and well tolerated. Conclusions Relugolix 40 mg in combination with E2 1 mg and NETA 0.5 mg provided systemic E2 concentrations within a range expected to minimize the risk of undesirable effects of hypoestrogenism associated with the administration of relugolix alone. Clinical Trial Registration Clinicaltrials.gov identifier no. NCT04978688. Trial registration date: 27 July, 2021; retrospectively registered.Keywords
This publication has 22 references indexed in Scilit:
- Estradiol reference intervals in women during the menstrual cycle, postmenopausal women and men using an LC-MS/MS methodClinica Chimica Acta, 2019
- Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: Studies in human GnRH receptor knock-in miceEuropean Journal of Pharmacology, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of EndometriosisCPT: Pharmacometrics & Systems Pharmacology, 2012
- Design and Analysis of Bioavailability and Bioequivalence Studies2008
- Norethindrone acetate and estradiol-induced endometrial hyperplasiaObstetrics & Gynecology, 2000
- Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetateObstetrics & Gynecology, 1999
- 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapyMaturitas, 1996
- Hormone treatment of endometriosis: The estrogenthreshold hypothesisAmerican Journal of Obstetrics and Gynecology, 1992
- Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesisAmerican Journal of Obstetrics and Gynecology, 1990